CIRCULAR DATED 16 JULY 2026

THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.

This Circular is issued by Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the "**Company**"). **If you are in any doubt as to the action you should take, you should consult your stockbroker, bank manager, solicitor, accountant or other professional adviser(s) immediately.**

If you have sold all your shares in the capital of the Company, you should immediately hand this Circular, the Notice of Extraordinary General Meeting and the accompanying Proxy Form to the purchaser or to the bank, stockbroker or agent through whom the sale or transfer was effected, for onward transmission to the purchaser or transferee.

The Singapore Exchange Securities Trading Limited assumes no responsibility for the accuracy of any statements or opinions made or reports contained in this Circular.

达仁堂
DA REN TANG
SINCE 1522

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED

(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

CIRCULAR TO SHAREHOLDERS

in relation to

(1) THE PROPOSED ADOPTION OF THE REMUNERATION POLICY FOR DIRECTORS AND SENIOR MANAGEMENT (《董事、高级管理人员薪酬管理制度》); AND

(2) THE DIRECTORS' REMUNERATION PROPOSAL FOR 2026 (《2026年度董事薪酬方案》)

IMPORTANT DATES AND TIMES

Last date and time for lodgement of Proxy Form	:	29 July 2026 at 2:00 p.m.
Date and time of Extraordinary General Meeting	:	31 July 2026 at 2:00 p.m.
Place of Extraordinary General Meeting	:	171 Chin Swee Road, CES Centre, Level 2, #02-14, Singapore 169877

TABLE OF CONTENTS

DEFINITIONS

The following definitions apply throughout this Circular unless the context otherwise requires or otherwise stated:

"2026 1st EGM"	:	The 1st EGM of the Company to be held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the PRC 300193 (concurrently, via video conferencing at 171 Chin Swee Road, CES Centre, Level 2, #02-14, Singapore 169877 for S-Share Shareholders in Singapore) on Friday, 31 July 2026 at 2:00 p.m.
"A-Shares"	:	Ordinary shares issued by the Company under the PRC Company Law, comprising shares issued to natural and legal persons in the PRC and which are denominated in RMB and listed on the SSE
"A-Share Shareholders"	:	Holders of A-Shares
"Articles" or *"Articles of Association"*	:	The articles of association of the Company, as amended, modified and/or supplemented from time to time
"associate"	:	(a) In relation to any Director, chief executive officer, Substantial Shareholder or Controlling Shareholder (being an individual) means: (i) his immediate family; (ii) the trustees of any trust of which he or his immediate family is a beneficiary or, in the case of a discretionary trust, is a discretionary object; and (iii) any company in which he and his immediate family together (directly or indirectly) have an interest of thirty per cent. (30%) or more; and (b) In relation to a Substantial Shareholder or Controlling Shareholder (being a company) means any other company which is its subsidiary or holding company or is a subsidiary of such holding company or one in the equity of which it and/or such other company or companies taken together (directly or indirectly) have an interest of thirty per cent. (30%) or more

"associated company"	:	In relation to a corporation, means: (a) any corporation in which the corporation or its subsidiary has, or the corporation and its subsidiary together have, a direct interest in voting shares of not less than twenty per cent. (20%) but not more than fifty per cent. (50%) of the total votes attached to all voting shares in the corporation; or (b) any corporation, other than a subsidiary of the corporation or a corporation which is an associated company by virtue of paragraph (a), the policies of which the corporation or its subsidiary, or the corporation together with its subsidiary, is or are able to control or influence materially
"Board" or *"Board of Directors"*	:	The board of Directors of the Company from time to time, which, as at the Latest Practicable Date, comprises Ms. Wang Lei, Mr. Guo Min, Mr. Zhou Hong, Mr. Shang Mingjie, Ms. Mao Weiwen, Mr. Xing Jianhua, Mr. Yeo Guat Kwang, Ms. Zhai Shuping, and Mr. Zhong Ming
"CDP"	:	The Central Depository (Pte) Limited
"Circular"	:	This circular dated 16 July 2026
"Company"	:	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
"control"	:	The capacity to dominate decision-making, directly or indirectly, in relation to the financial and operating policies of a company
"Controlling Shareholder"	:	A person who: (a) holds directly or indirectly fifteen per cent. (15%) or more of the total voting rights in the Company. The SGX-ST may determine that a person who satisfies this paragraph is not a controlling shareholder; or (b) in fact exercises control over the Company
"CSRC"	:	China Securities Regulatory Commission (中国证券监督管理委员会)
"Directors"	:	The directors of the Company as at the Latest Practicable Date, and "*Director*" shall be construed accordingly
"EGM" or *"Extraordinary General Meeting"*	:	An extraordinary general meeting of the Company

"Group"	:	The Company and its subsidiaries
"Latest Practicable Date"	:	10 July 2026, being the latest practicable date prior to the despatch of this Circular
"Listing Manual"	:	The listing manual of the SGX-ST, as amended, modified and/or supplemented from time to time
"Notice of EGM"	:	The notice of the 2026 1st EGM dated 16 July 2026
"PRC"	:	People's Republic of China
"PRC CG Code"	:	The Code of Corporate Governance for Listed Companies (《上市公司治理准则》) promulgated by the CSRC, as amended, modified and/or supplemented from time to time
"PRC Company Law"	:	The Company Law of the PRC (《中华人民共和国公司法》), as amended, modified and/or supplemented from time to time
"Proxy Form"	:	The proxy form in respect of the 2026 1st EGM
"Remuneration Committee"	:	The remuneration committee of the Company from time to time, which, as at the Latest Practicable Date, comprises Mr. Yeo Guat Kwang, Ms. Mao Weiwen, and Ms. Zhai Shuping
"Register of Members"	:	The register of members of the Company as maintained by the Company's S-Shares Registrar and Singapore Shares Transfer Office, Boardroom Corporate & Advisory Services Pte. Ltd.
"Restricted A-Shares"	:	A-Shares granted under the Scheme which shall be subject to the terms and conditions of the Scheme
"S-Shares"	:	Ordinary shares issued by the Company under the PRC Company Law, comprising shares issued to natural and legal persons in countries other than PRC and which are denominated in US$ and are listed on the Official List of the SGX-ST
"S-Share Shareholders"	:	Holders of S-Shares

"Scheme"	:	The 2019 Restricted A-Share Incentive Scheme (2019年A股限制性股票计划) of the Company, which was established to further improve the long-term incentive mechanism of the Company, attract and retain outstanding talents, fully motivate the key personnel of the Company, and align the interests of the Shareholders and the Company with the individual interests of the members of the management team of the Company, so that all the aforementioned parties will make a joint effort for the long-term development of the Company. The incentive instruments issued under the Scheme are A-Shares only, and those eligible to participate in the Scheme include directors, members of senior management, members of the Company's management team whom the Board considers should be motivated, leading-level scientific research experts, core personnel for scientific research and technology, and members of the core management team of the subordinate enterprises of the Company (excluding the Company's associated companies)[1]
"securities accounts"	:	The securities account maintained with CDP, but not including the securities accounts maintained with a Depository Agent
"SFA"	:	The Securities and Futures Act 2001 of Singapore, as amended, modified and/or supplemented from time to time
"SGXNet"	:	Singapore Exchange Network, the corporate announcement system maintained by the SGX-ST for the submission of information and announcements by listed companies
"SGX-ST"	:	Singapore Exchange Securities Trading Limited
"Shareholders"	:	Registered holders of Shares (comprising A-Share Shareholders and S-Share Shareholders) except that where the registered holder is CDP, the term "*Shareholders*" in relation to Shares held by CDP shall mean the persons named as Depositors in the Depository Register maintained by CDP and to whose securities accounts such Shares are credited
"Shares"	:	Ordinary shares in the capital of the Company, comprising A-Shares and S-Shares
"SSE"	:	Shanghai Stock Exchange

1 For further details of the Scheme, please refer to the Company's circular dated 15 November 2019.

"SSE Listing Rules"	:	The Listing Rules of Shanghai Stock Exchange (《上海证券交易所股票上市规则》), as amended, modified and/or supplemented from time to time
"subsidiaries"	:	The subsidiaries of a corporation as determined in accordance with the laws of the PRC or Singapore (as the case may be), and "*subsidiary*" shall be construed accordingly
"Substantial Shareholder"	:	A person who has an interest or interests in one (1) or more voting Shares (excluding treasury shares) in the Company, and the total votes attached to that Share, or those Shares, represent not less than five per cent. (5%) of the total votes attached to all the voting Shares (excluding treasury shares) in the Company
"TPH"	:	Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司), the Controlling Shareholder of the Company holding approximately 43.059% of the issued share capital of the Company as at the Latest Practicable Date

Currencies, units and others

"RMB"	:	Renminbi, being the lawful currency of the PRC
"S$"	:	Singapore Dollars, being the lawful currency of the Republic of Singapore
"US$"	:	United States Dollars, being the lawful currency of the United States of America
"%" or *"per cent."*	:	Percentage or per centum

The terms "**Depositor**", "**Depository**", "**Depository Register**" and "**Depository Agent**" shall have the meanings ascribed to them respectively in Section 81SF of the SFA.

Words importing the singular shall, where applicable, include the plural and *vice versa*. Words importing the masculine gender shall, where applicable, include the feminine and neuter genders and *vice versa*. References to persons shall, where applicable, include corporations.

Any reference in this Circular to any enactment is a reference to that enactment as for the time being amended or re-enacted. Any term defined under the Listing Manual, the SFA or any statutory modification thereof and not otherwise defined in this Circular shall, where applicable, have the same meaning ascribed to it under the Listing Manual, the SFA or any statutory modifications thereof, as the case may be, unless the context otherwise requires.

Any reference to a time of a day in this Circular is a reference to Singapore time, unless otherwise stated.

Any discrepancies in this Circular between the sum of the figures stated and the totals thereof are due to rounding. Accordingly, figures shown as totals in this Circular may not be an arithmetic aggregation of the figures which precede them.

The English names of certain PRC companies, entities and authorities in this Circular are translations of their Chinese names, as there is no requirement for these companies, entities and authorities to have official English names. In case of any discrepancy, conflict or inconsistency among English translations, please refer to the original Chinese names.

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED

(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

Board of Directors	**Registered Office**
Ms. Wang Lei (Chairman and Executive Director)	17 Baidi Road, Nankai District, Tianjin, the PRC
Mr. Guo Min (Executive Director)	
Mr. Zhou Hong (Executive Director)	
Mr. Shang Mingjie (Executive Director)	
Ms. Mao Weiwen (Non-Executive and Non-Independent Director)	
Mr. Xing Jianhua (Non-Executive and Non-Independent Director)	
Mr. Yeo Guat Kwang (Lead Independent and Non-Executive Director)	
Ms. Zhai Shuping (Independent and Non-Executive Director)	
Mr. Zhong Ming (Independent and Non-Executive Director)	

16 July 2026

To: The Shareholders of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Dear Sir/Madam

(1) THE PROPOSED ADOPTION OF THE REMUNERATION POLICY FOR DIRECTORS AND SENIOR MANAGEMENT (《董事、高级管理人员薪酬管理制度》); AND

(2) THE DIRECTORS' REMUNERATION PROPOSAL FOR 2026 (《2026年度董事薪酬方案》)

1. INTRODUCTION

1.1 2026 1st EGM

The Directors are convening the 2026 1st EGM to be held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the PRC 300193 (concurrently, via video conferencing at 171 Chin Swee Road, CES Centre, Level 2, #02-14, Singapore 169877 for S-Share Shareholders in Singapore) on Friday, 31 July 2026 at 2:00 p.m. to seek Shareholders' approval for:

(a) the proposed adoption of the remuneration policy for directors and senior management (《董事、高级管理人员薪酬管理制度》) (the "**Remuneration Policy**"); and

(b) the directors' remuneration proposal for 2026 (《2026年度董事薪酬方案》) (the "**Directors' Remuneration Proposal**"),

(collectively, the "**Proposals**"), as further elaborated in Sections 2 and 3 below.

The Notice of EGM is set out on pages N-1 to N-3 of this Circular.

1.2 Purpose of this Circular

The purpose of this Circular is to provide Shareholders with information pertaining to, and to seek Shareholders' approval for, the Proposals.

If you are in any doubt as to the action you should take, you should consult your stockbroker, bank manager, solicitor, accountant or other professional adviser(s) immediately.

1.3 SGX-ST

The SGX-ST assumes no responsibility for the accuracy of any statements or opinions made or reports contained in this Circular.

1.4 Legal Adviser

Shook Lin & Bok LLP is the legal adviser to the Company as to Singapore law in relation to the Proposals.

2. THE PROPOSED ADOPTION OF THE REMUNERATION POLICY

2.1 Background

The Code of Corporate Governance for Listed Companies (《上市公司治理准则》) (i.e. the PRC CG Code), as revised by the China Securities Regulatory Commission (中国证券监督管理委员会) (i.e. the CSRC) in 2025, took effect on 1 January 2026. Pursuant to the PRC CG Code and the related implementation requirements issued by the CSRC, PRC-listed companies are required to formulate, or, where applicable, review and enhance, their remuneration management policies for directors and senior management. Such policies are required to reflect the relevant requirements of the PRC CG Code, including the establishment of mechanisms for determining the aggregate remuneration pool, the remuneration structure for directors and senior management, performance assessment, remuneration payment, and malus and clawback arrangements, while taking into account each company's particular business and operational circumstances. Specifically, the Company is required by the CSRC to complete the formulation of its remuneration policy for Directors and Senior Management and obtain the requisite Shareholders' approval by 31 July 2026.

Accordingly, the Company proposes to adopt the Remuneration Policy, which shall apply to all Directors and members of Senior Management, including, among others, the chief executive officer (or its equivalent, namely the general manager), deputy general managers, the chief financial officer (or its equivalent, namely the chief accountant), and the secretary to the Board. The Remuneration Policy is intended to further enhance the Company's management standards, establish an effective incentive and accountability framework, develop a remuneration framework that promotes both internal equity and external competitiveness, and strengthen the Company's market competitiveness and capacity for sustainable development. In formulating the Remuneration Policy, the Company has also taken into account the applicable requirements under the Listing Manual relating to the structure and approval of directors' fees and the remuneration of executive directors, as well as the Code of Corporate Governance 2018 relating to the procedures for developing remuneration policies and the level and mix of remuneration.

The Remuneration Policy has been formulated and reviewed by the Remuneration Committee and considered by the Board. Its adoption is subject to the approval of the Shareholders at the 2026 1st EGM.

2.2 Summary of Key Features of the Remuneration Policy

The key features of the Remuneration Policy are summarised below:

(a) The Remuneration Policy sets out the remuneration framework applicable to Directors and Senior Management of the Company, including the respective responsibilities of the general meeting, the Board and the Remuneration Committee in relation to remuneration policies, remuneration proposals and performance assessment matters.

(b) Directors who hold executive positions within the Company and Senior Management are remunerated through annual cash remuneration and, where applicable, long-term incentive awards. Annual cash remuneration comprises fixed annual remuneration, performance-related annual remuneration and allowances. Independent Directors are entitled to fixed directors' fees, which are not performance-related remuneration and are not determined by reference to performance assessment outcomes, while Non-Independent Directors who do not hold full-time management positions within the Company or its subsidiaries do not receive any remuneration or directors' fees from the Company, notwithstanding their responsibilities as members of the Board.

(c) The performance-related annual remuneration of Directors who hold executive or management positions within the Company and Senior Management is linked to the Company's overall operating results and the individual's performance. The relevant performance indicators are derived from the Company's strategic objectives and annual business targets, and may include financial indicators and individual performance indicators, as well as compliance and control indicators.

(d) Long-term incentive arrangements may be separately formulated. To the extent that any long-term incentive arrangement involves any share incentive scheme, employee share ownership plan, share-based scheme or issue of securities, the Company will comply with the applicable requirements under the Listing Manual and the SSE Listing Rules, including any requirement to obtain Shareholders' approval.

(e) The Remuneration Policy provides for malus and clawback arrangements. In particular, where the Company is required to restate its financial statements due to financial misstatements, fraud or other similar circumstances, or where a Director or member of Senior Management breaches his or her duties and thereby causes loss to the Company or is responsible for any financial misstatement, misappropriation of funds, unauthorised guarantees or other regulatory breaches, the Company may, having regard to the circumstances, reduce, suspend or withhold any unpaid performance-related remuneration and long-term incentive awards, and/or recover all or part of any performance-related remuneration and long-term incentive awards previously paid in respect of the relevant period.

The full text of the Remuneration Policy is set out in **Appendix A** to this Circular.

3. THE DIRECTORS' REMUNERATION PROPOSAL FOR 2026

3.1 Overview

In accordance with the PRC Company Law, the PRC CG Code and the Articles of Association of the Company, taking into account the Company's business needs and operating circumstances and having regard to prevailing market practice and remuneration levels in the relevant industry and region, the Company has prepared the Directors' Remuneration Proposal for 2026 (i.e. the Directors' Remuneration Proposal).

The Directors' Remuneration Proposal, covering the remuneration arrangements applicable to all Directors of the Company for 2026, has been formulated and reviewed by the Remuneration Committee and considered by the Board. All Directors abstained from voting on the Board resolution relating to the Directors' Remuneration Proposal. In accordance with applicable PRC laws, including the PRC Company Law and the PRC CG Code, as well as the Articles of Association of the Company, the Directors' Remuneration Proposal is being submitted to the Shareholders for consideration and approval at the 2026 1st EGM.

For the avoidance of doubt, as the Company is incorporated in the PRC and is not a company incorporated in Singapore, no approval under the Companies Act 1967 of Singapore is required in respect of the Directors' Remuneration Proposal. Subject to compliance with the applicable requirements under the Listing Manual and the Code of Corporate Governance 2018, the Company is not aware of any other approval required under applicable Singapore laws or regulations in respect of the Directors' Remuneration Proposal.

3.2 Principal Terms of the Directors' Remuneration Proposal

The principal terms of the Directors' Remuneration Proposal are set out below.

(a) Scope of Application

This Directors' Remuneration Proposal applies to all Directors of the Company.

(b) Term

This Directors' Remuneration Proposal shall apply for the period from 1 January 2026 to 31 December 2026.

(c) Remuneration Arrangements

(i) Independent Directors

Independent Directors shall be entitled to directors' fees.

The annual directors' fees payable to Independent Directors shall be as follows:

(A) S$55,000 per annum (before tax) for each Singapore-based Independent Director; and

(B) RMB100,000 per annum (before tax) for each PRC-based Independent Director.

In formulating the Directors' Remuneration Proposal, the Remuneration Committee has taken into account various factors, including the respective roles and responsibilities, effort, time commitment and performance of duties of the Directors, as well as prevailing market remuneration levels. In the case of Independent Directors, the difference between the directors' fees payable to Singapore-based Independent Directors and PRC-based Independent Directors primarily reflects the differences in prevailing market remuneration levels for independent directors in the Singapore and PRC capital markets. Having regard to the different living costs in their respective places of residence, the directors' fees payable to Singapore-based Independent Directors have been determined by reference to the prevailing remuneration levels of independent directors of listed companies in Singapore, while the directors' fees payable to PRC-based Independent Directors have been determined by reference to the prevailing remuneration levels of independent directors of listed companies in the PRC. The directors' fees payable to Independent Directors are fixed annual fees and include all fees payable in respect of their service as chairpersons or members of the Board committees. No other allowances are payable by the Company to the Independent Directors.

The directors' fees may be paid annually, quarterly or monthly, as may be agreed between the Company and the relevant Independent Director.

(ii) Non-Independent Directors

Non-Independent Directors who hold full-time management positions within the Company or its subsidiaries shall be remunerated in accordance with the Company's remuneration policies and practices. Non-Independent Directors who do not hold full-time management positions within the Company or its subsidiaries shall not receive any remuneration or directors' fees from the Company, notwithstanding their responsibilities as members of the Board.

(d) Other Matters

(i) Any individual income tax payable in respect of the remuneration described in the Directors' Remuneration Proposal shall be withheld and remitted by the Company in accordance with applicable laws and regulations.

(ii) Reasonable expenses incurred by Directors in attending meetings of the Board, Board committees and general meetings of the Company, and in connection with the performance of their duties as Directors, shall be borne by the Company.

(iii) In the event of breach of any applicable laws or regulations, the Articles of Association of the Company or other material governance documents, or where a Director causes material economic loss or a material adverse impact to the Company, the Company may, in accordance with its applicable policies and procedures, recover all or part of any performance-related remuneration and long-term incentive awards previously paid in respect of the relevant period. For the avoidance of doubt, the fixed directors' fees payable to Independent Directors do not constitute performance-related remuneration or long-term incentive awards and are not subject to such clawback or recovery arrangements.

4. DIRECTORS' AND SUBSTANTIAL SHAREHOLDERS' INTERESTS

4.1 Directors' and Substantial Shareholders' Interests in Shares

The details of the Directors' and Substantial Shareholders' interests in the Shares as at the Latest Practicable Date are set out below:

	Direct Interest		Deemed Interest	
	No of Shares	**%**(1)	**No of Shares**	**%**(1)
Directors				
Wang Lei	–	–	–	–
Guo Min	–	–	331,593,428	43.059
Zhou Hong	23,800(2)	0.003	–	–
Shang Mingjie	–	–	–	–
Mao Weiwen	–	–	–	–
Xing Jianhua	–	–	–	–
Yeo Guat Kwang	–	–	–	–
Zhai Shuping	–	–	–	–
Zhong Ming	–	–	–	–
Substantial Shareholders (other than Substantial Shareholders who are Directors)				
TPH	325,855,528	42.314	5,737,900(3)	0.745

Notes:

(1) Based on the total issued share capital of 770,094,356 Shares as at the Latest Practicable Date.

(2) These are the Restricted A-Shares granted and issued under the Scheme.

(3) Pursuant to Section 4 of the SFA, TPH is deemed interested in the 5,737,900 Shares in the capital of the Company held by its wholly-owned subsidiary, Jinyao Global Pte. Ltd. (formerly known as Tianjin Pharmaceutical (Singapore) International Investment Pte. Ltd.).

4.2 Directors' and Substantial Shareholders' Interests in the Proposals

The Directors are regarded as interested in the Directors' Remuneration Proposal insofar as it concerns their remuneration or remuneration framework. Accordingly, all Directors have abstained from voting on the Board resolution in respect of the Directors' Remuneration Proposal and will also abstain from making any recommendation to the Shareholders on the Directors' Remuneration Proposal. In addition, any Director who is also a Shareholder and his or her associates (where applicable) will abstain from voting on the resolution relating to the Directors' Remuneration Proposal at the 2026 1st EGM and will not accept appointments as proxies or otherwise participate in voting on the aforesaid resolution at the 2026 1st EGM, unless specific instructions have been given in the proxy instrument on how the relevant Shareholders wish their votes to be cast. The Company will disregard any votes cast on the resolution in respect of the Directors' Remuneration Proposal by such persons.

As at the Latest Practicable Date, none of the Substantial Shareholders has any interest, direct or indirect, in the Proposals, other than through their respective shareholdings in the Company (if any) as disclosed in Section 4.1 of this Circular.

5. DIRECTORS' RECOMMENDATIONS

5.1 The Proposed Adoption of the Remuneration Policy

The Directors, having considered, amongst other things, the background and purpose of the Remuneration Policy, are of the opinion that the proposed adoption of the Remuneration Policy is in the best interests of the Company and its Shareholders as a whole. Accordingly, the Directors recommend that the Shareholders **VOTE IN FAVOUR** of the resolution relating to the proposed adoption of the Remuneration Policy, as set out in the Notice of EGM.

5.2 The Directors' Remuneration Proposal

All Directors have abstained from making any recommendation to Shareholders on the Directors' Remuneration Proposal, as set out in the Notice of EGM.

6. EXTRAORDINARY GENERAL MEETING

The 2026 1st EGM, notice of which is set out on pages N-1 to N-3 of this Circular, will be held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the PRC 300193 (concurrently, via video conferencing at 171 Chin Swee Road, CES Centre, Level 2, #02-14, Singapore 169877 for S-Share Shareholders in Singapore) on Friday, 31 July 2026 at 2:00 p.m. for the purpose of considering and, if thought fit, passing the resolutions (with or without modifications) as set out in the Notice of EGM.

S-Share Shareholders may participate in the 2026 1st EGM via the video conferencing at 171 Chin Swee Road, CES Centre, Level 2, #02-14, Singapore 169877 for S-Share Shareholders in Singapore by:

(a) attending the 2026 1st EGM in person;

(b) submitting substantial and relevant questions relating to the resolutions to be tabled for approval at the 2026 1st EGM, in advance of, or at, the 2026 1st EGM; and/or

(c) voting at the 2026 1st EGM (i) themselves, or (ii) through their duly appointed proxy(ies).

Details of the submission of questions and voting at the 2026 1st EGM by Shareholders (including S-Share Shareholders) are set out in the Notice of EGM.

7. ACTION TO BE TAKEN BY S-SHARE SHAREHOLDERS

S-Share Shareholders who wish to vote but who are unable to attend the 2026 1st EGM and wish to appoint a proxy or proxies to attend and vote at the 2026 1st EGM on their behalf must complete, sign and return the Proxy Form in accordance with the instructions printed thereon as soon as possible and, in any event, ensure that it is received (i) by post at the office of the Company's S-Shares Registrar and Singapore Shares Transfer Office, Boardroom Corporate & Advisory Services Pte. Ltd., at 1 Harbourfront Avenue, Keppel Bay Tower #14-07, Singapore 098632, or (ii) by email at Srs.Proxy@boardroomlimited.com, no later than **2:00 p.m.** on **Wednesday**, **29 July 2026**.

The completion and return of a Proxy Form by a S-Share Shareholder does not preclude such S-Share Shareholder from attending, speaking and voting in person at the 2026 1st EGM should they subsequently decide to do so. In such an event, the appointment of the proxy(ies) for the 2026 1st EGM will be deemed to be revoked upon the S-Share Shareholder's attendance at the 2026 1st EGM in person, and the Company reserves the right to refuse to admit any person(s) appointed under the Proxy Form to the 2026 1st EGM.

A S-Share Shareholder who intends to attend the 2026 1st EGM must be registered in the Register of Members or, if the registered holder is CDP, must be named as a Depositor in the Depository Register, as at a time not earlier than forty-eight (48) hours before the 2026 1st EGM.

8. DIRECTORS' RESPONSIBILITY STATEMENT

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this Circular and confirm after making all reasonable enquiries that, to the best of their knowledge and belief, this Circular constitutes full and true disclosure of all material facts about the Proposals and the Group, and the Directors are not aware of any facts the omission of which would make any statement in this Circular misleading.

Where information in this Circular has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in this Circular in its proper form and context.

9. DOCUMENT AVAILABLE FOR INSPECTION

A copy of the Articles of Association of the Company is available for inspection at the registered office of the Company at 17 Baidi Road, Nankai District, Tianjin, the PRC 300193, during normal business hours from the date of this Circular up to and including the date of the 2026 1st EGM.

Yours faithfully
For and on behalf of the Board of Directors of
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Wang Lei
Chairman of the Board

津药达仁堂集团股份有限公司
董事、高级管理人员薪酬管理制度
REMUNERATION POLICY FOR DIRECTORS AND SENIOR MANAGEMENT OF TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED

第一章 总则
CHAPTER 1 GENERAL PROVISIONS

第一条 目的
Article 1 Purpose

为进一步提高津药达仁堂集团股份有限公司（以下简称“公司”）经营管理水平，建立科学有效的激励与约束机制，形成兼具内部公平性和外部竞争性的薪酬管理机制，提升企业市场竞争力和发展引领力，根据相关法律、行政法规、规范性文件和公司章程的规定，结合公司实际情况，制定本制度。

This Remuneration Policy for Directors and Senior Management (the “**Remuneration Policy**”) is established to further enhance the management standards of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (the “**Company**”), establish an effective incentive and accountability framework, develop a remuneration framework that promotes both internal equity and external competitiveness, and strengthen the Company’s market competitiveness and capacity for sustainable development. This Remuneration Policy has been prepared in accordance with the applicable laws, administrative regulations and regulatory requirements, as well as the Articles of Association of the Company, and taking into account the actual circumstances of the Company.

第二条 原则
Article 2 Guiding Principles

(一) 战略导向，分类激励。以战略规划为基础，对标市场水平和行业实践，保障薪酬的市场竞争力和未来适用性，满足公司对转型发展的要求；对“高精尖缺”人才，实行市场化灵活的薪酬机制，链接市场水平及个人贡献。

(a) Strategic Orientation and Differentiated Incentives. Based on the Company’s strategic plans and with reference to market levels and industry practices, the remuneration framework shall remain competitive and support the Company’s future development needs. For high-calibre, specialised and scarce talent, the Company may adopt market-oriented and flexible remuneration arrangements, taking into account prevailing market levels and individual contributions.

(二) 统筹兼顾，保障公平。通过组织梳理、市场对标和组织称重，形成合理的薪酬架构，完善薪酬监管机制，同时合理统筹管理层与普通职工的收入分配关系，确保职工工资增长与公司经营发展同步。

(b) Balanced Consideration and Fairness. The Company shall establish an appropriate remuneration structure and improve its remuneration governance mechanisms through organisational reviews, market benchmarking and job evaluation. The Company shall also maintain a reasonable balance between the remuneration of management and employees, and ensure that employee remuneration growth is aligned with the Company’s business development.

(三) 挂钩绩效，凸显差异。强化薪酬配套的绩效关联机制，坚持薪酬与公司经营业绩和个人绩效紧密挂钩，确保“业绩升，薪酬升，业绩降，薪酬降”的有效实施。

(c) Performance Linkage and Differentiation. The Company shall strengthen the linkage between remuneration and performance, ensuring that remuneration is closely aligned with the

Disclaimer: *The English version of the Remuneration Policy for Directors and Senior Management is an unofficial translation of its Chinese version. In the event of any inaccuracy, conflict or inconsistency between the two versions, the Chinese version shall prevail.*

Company's operating results and individual performance. Remuneration shall be adjusted, where appropriate, to reflect performance outcomes.

(四) 完善结构，短长结合。逐步建立健全"短、中、长"结合的市场化全面薪酬机制，探索符合公司发展需求的中长期激励约束机制，为经营管理团队注入长期意识，引导长远目标的实现，并在此过程中实现发展成果共享。

(d) Optimised Structure and Long-Term Orientation. The Company shall progressively establish a market-oriented remuneration framework comprising short-term, medium-term and long-term incentives, and explore medium- and long-term incentive and accountability mechanisms that support the Company's development needs. Such framework is intended to promote a long-term perspective among the management team, support the achievement of long-term objectives and enable employees and management to share in the Company's development outcomes.

第三条 适用范围
Article 3 Scope of Application

本制度适用于公司董事、高级管理人员。
This Remuneration Policy applies to the Directors and Senior Management of the Company.

第二章 管理职责和分工
CHAPTER 2 RESPONSIBILITIES AND GOVERNANCE STRUCTURE

第四条 股东会
Article 4 General Meeting

决定董事和高级管理人员薪酬管理制度，决定董事薪酬方案，决定董事年度考核方案及结果。
The general meeting of the Company shall:

(a) approve the remuneration policy for Directors and Senior Management;

(b) approve the remuneration proposal for Directors; and

(c) approve the annual performance assessment framework for Directors and the results of such assessment.

第五条 董事会
Article 5 Board of Directors

审议董事和高级管理人员薪酬管理制度，审议董事薪酬方案，决定高级管理人员薪酬方案，决定高级管理人员年度考核方案及结果。
The Board shall:

(a) review the remuneration policy for Directors and Senior Management;

(b) review the remuneration proposal for Directors;

(c) approve the remuneration proposal for Senior Management; and

(d) approve the annual performance assessment framework for Senior Management and the results of such assessment.

第六条 董事会薪酬与考核委员会
Article 6 Remuneration Committee

公司董事会下设薪酬与考核委员会，负责制定董事、高级管理人员的考核标准并进行考核，制定、审查董事、高级管理人员的薪酬政策与方案，就如下事项提出建议：

The Board has established a Remuneration Committee, which shall be responsible for formulating performance assessment criteria for Directors and Senior Management and conducting performance assessments, as well as formulating and reviewing remuneration policies and remuneration proposals relating to Directors and Senior Management, and making recommendations to the Board on the following matters:

(一) 董事、高级管理人员的薪酬；
(a) the remuneration of Directors and Senior Management;

(二) 制定或者变更股权激励计划、员工持股计划，激励对象获授权益、行使权益条件成就；
(b) the formulation or amendment of share incentive schemes and employee share ownership plans, and matters relating to the grant of awards or rights to incentive participants and the satisfaction of the conditions for the exercise or vesting of such awards or rights;

(三) 董事、高级管理人员在拟分拆所属子公司安排持股计划；
(c) shareholding arrangements for Directors and Senior Management in connection with any proposed spin-off of the Company's subsidiaries; and

(四) 法律法规和公司章程规定的其他事项。
(d) such other matters as may be required under applicable laws and regulations or the Articles of Association of the Company.

第三章 绩效与履职评价
CHAPTER 3 PERFORMANCE ASSESSMENT AND DUTY EVALUATION

第七条 评价周期
Article 7 Assessment Cycle

董事和高级管理人员绩效与履职评价以自然年为周期。

The performance assessment and duty evaluation of Directors and Senior Management shall be conducted on an annual basis, with each assessment cycle corresponding to a calendar year.

第八条 评价方式和维度
Article 8 Assessment Methods and Criteria

(一) 独立董事
(a) Independent Directors

独立董事履职评价采取自我评价、相互评价的方式进行。评价维度包括但不限于独立性保持、履职尽责、忠实勤勉程度等。

The duty evaluation of Independent Directors shall be conducted through self-assessment and peer assessment. The assessment criteria shall include, but not be limited to:

(i) maintenance of independence;

(ii) performance of duties and responsibilities; and

(iii) diligence and loyalty in the discharge of duties.

(二) 董事和高级管理人员
(b) Directors Holding Executive Positions and Senior Management

在公司担任行政职务的董事和高级管理人员采取经营业绩考核的方式，经营业绩考核指标来源于公司战略和年度经营目标分解，包括但不限于财务指标、个性化指标、制约类指标，指标具体设定规则、权重、目标值等在年度绩效合约中予以明确。
Directors who hold executive or management positions within the Company and Senior Management shall be assessed based on business performance.

The performance indicators shall be derived from the Company's strategic objectives and annual business targets and may include, without limitation:

(i) financial indicators;

(ii) individual performance indicators; and

(iii) compliance and control indicators.

The specific performance indicators, weightings, targets and related assessment criteria shall be set out in the annual performance agreement.

第四章 薪酬结构与水平
CHAPTER 4 REMUNERATION STRUCTURE

第九条 独立董事
Article 9 Independent Directors

独立董事采用固定年度津贴制，其津贴不得与公司的利润或营业额挂钩，亦不得按公司的利润或营业额提取佣金或按其一定比例计算。独立董事行使职责所需的合理费用由公司承担。
Independent Directors shall be entitled to fixed annual directors' fees, which shall not be linked to the profits or turnover of the Company or calculated by reference to any commission on, or percentage of, the profits or turnover of the Company. Reasonable expenses incurred by Independent Directors in the discharge of their duties shall be borne by the Company.

第十条 不在公司担任行政职务的董事
Article 10 Directors Not Holding Executive Positions

未在公司担任行政职务的董事，尽管履行董事职责，不在公司领取薪酬或董事津贴。
Directors who do not hold executive or management positions within the Company shall not receive any remuneration or directors' fees from the Company, notwithstanding their responsibilities as members of the Board.

第十一条 在公司担任行政职务的董事、高级管理人员
Article 11 Directors Holding Executive Positions and Senior Management

(一) 在公司担任行政职务的董事和高级管理人员年度薪酬由年度现金薪酬和中长期激励构成。本制度适用于年度现金薪酬的管理，中长期激励方案另行制定。为免生疑问，在公司担任行政职务的董事的薪酬不得包括按公司营业额提取的佣金，亦不得按公司营业额的一定比例计算。
(a) The annual remuneration of Directors who hold executive or management positions within the Company and Senior Management shall comprise annual cash remuneration and long-term

incentive awards. This Remuneration Policy governs the administration of annual cash remuneration. Long-term incentive arrangements shall be governed by separate policies or plans. For the avoidance of doubt, the remuneration payable to Directors who hold executive or management positions within the Company shall not include any commission on, or be calculated by reference to any percentage of, the turnover of the Company.

(二) 年度现金薪酬由基本年薪、绩效年薪和补贴构成。其中绩效年薪占基本年薪与绩效年薪总额的比例原则上不低于50%。

(b) Annual cash remuneration shall comprise:

(i) fixed annual remuneration;

(ii) performance-related annual remuneration; and

(iii) allowances.

The performance-related annual remuneration component shall generally account for not less than 50% of the aggregate amount of fixed annual remuneration and performance-related annual remuneration.

1. 基本年薪是指根据所任职岗位和个人能力确定的年度固定收入。

(i) Fixed annual remuneration refers to the annual fixed income determined based on the individual's position and capabilities.

2. 绩效年薪是指与公司整体经营业绩和个人绩效结果相挂钩的浮动奖金。

(ii) Performance-related annual remuneration refers to variable remuneration linked to the Company's overall operating results and the individual's performance.

3. 补贴是指公司对履行职责提供的相应现金补贴，包括交通补贴、通讯补贴等，具体执行标准和形式根据相关规定执行。

(iii) Allowances refer to cash allowances provided by the Company in connection with the performance of duties, including transportation allowances, communication allowances and other allowances, which shall be administered in accordance with the relevant policies of the Company.

第十二条 年度薪酬确定依据及具体构成在薪酬方案中明确。

Article 12 The basis for determining annual remuneration and the detailed remuneration structure shall be set out in the relevant remuneration proposal.

第五章 薪酬管理
CHAPTER 5 REMUNERATION ADMINISTRATION

第十三条 本制度中年度现金薪酬均为税前薪酬。公司依据相关规定代扣代缴应当由个人承担的各项社会保险费、住房公积金、个人所得税以及法律法规规定可以扣除的费用。

Article 13 All annual cash remuneration referred to in this Remuneration Policy is on a pre-tax basis. The Company shall make all statutory deductions and withholdings required under applicable laws and regulations, including deductions for the relevant individual's social insurance contributions, housing provident fund contributions and individual income tax.

第十四条 薪酬的兑现与发放
Article 14 Payment of Remuneration

(一) 独立董事
(a) Independent Directors

独立董事津贴为经股东会批准的固定金额，自股东会审议通过其任职决议之日起计算，津贴发放频次由双方协商确定，可按年度、季度或月度发放。

Directors' fees payable to Independent Directors shall be fixed sums as approved by the shareholders in general meeting and shall accrue from the date on which the relevant appointment is approved by the shareholders in general meeting. The payment frequency of such fees may be determined by agreement between the Company and the relevant Independent Director, and such fees may be paid annually, quarterly or monthly.

(二) 在公司担任行政职务的董事、高级管理人员
(b) Directors Holding Executive Positions and Senior Management

1. 基本年薪依据在职时间按月平均发放。月度发放标准=基本年薪标准/12，以货币形式支付。

(i) Fixed annual remuneration shall be paid monthly in cash. The monthly payment shall be calculated by dividing the applicable fixed annual remuneration by twelve (12), with the total amount payable being pro-rated based on the individual's actual period of service.

2. 绩效年薪根据董事、高级管理人员绩效合约的考核结果兑现，逐步探索绩效薪酬递延支付机制，于次年在公司年度报告披露及绩效评价完成后进行发放。

(ii) Performance-related annual remuneration shall be determined based on the outcome of the assessment under the relevant annual performance agreement. The Company may progressively introduce a deferred payment mechanism for performance-related annual remuneration. Such remuneration shall generally be paid in the following year after the publication of the Company's annual report and the completion of the performance assessment process.

3. 补贴根据公司相关规定执行，原则上以货币形式发放。

(iii) Allowances shall be administered in accordance with the relevant policies of the Company and shall generally be paid in cash.

第十五条 薪酬调整
Article 15 Adjustment of Remuneration

在董事津贴增加需经股东会批准（如适用）的前提下，董事、高级管理人员的薪酬将随着公司经营状况的变化相应的调整，以适应公司进一步的发展需要。薪酬调整依据为：

Subject to any requisite approval of the shareholders in general meeting for an increase in Directors' fees, the remuneration of Directors and Senior Management may be adjusted from time to time having regard to the Company's operating performance, business conditions and development needs. Such adjustments may take into account the following factors:

(一) 同行业薪酬水平：定期通过市场薪酬报告或公开的薪酬数据，收集同行业的薪酬数据，并进行汇总分析，作为公司薪酬调整的参考依据。

(a) remuneration levels within the relevant industry, based on market remuneration surveys and publicly available remuneration data;

(二) 公司盈利状况。
(b) the Company's profitability;

(三) 公司组织结构调整。
(c) organisational restructuring within the Company;

(四) 岗位或职责发生变动的个别调整。
(d) changes in the duties or responsibilities of the relevant individual;

(五) 个人业绩贡献。
(e) the individual's performance and contribution; and

(六) 其他经公司董事会/股东会按法定权限审议决定的相关合理调整事项。
(f) any other reasonable adjustments approved by the Board or by the shareholders in general meeting within the scope of their respective statutory authority.

第六章 薪酬的止付追索
CHAPTER 6 MALUS AND CLAWBACK

第十六条 公司因财务造假等错报对财务报告进行追溯重述时，应当及时对董事、高级管理人员绩效薪酬和中长期激励收入予以重新考核并相应追回超额发放部分。

Article 16 Where the Company is required to restate its financial statements due to financial misstatements, fraud or other similar circumstances, the Company shall promptly reassess the performance-related remuneration and long-term incentive awards granted to Directors and Senior Management and shall take appropriate steps to recover any excess amounts previously paid.

第十七条 董事、高级管理人员违反义务给上市公司造成损失，或者对财务造假、资金占用、违规担保等违法违规行为负有过错的，上市公司应当根据情节轻重减少、停止支付未支付的绩效薪酬和中长期激励收入，并对相关行为发生期间已经支付的绩效薪酬和中长期激励收入进行全额或部分追回。

Article 17 Where a Director or member of Senior Management breaches his or her duties and thereby causes loss to the Company, or is responsible for any financial misstatement, misappropriation of funds, unauthorised guarantees or other regulatory breaches, the Company shall, having regard to the circumstances:

(a) reduce, suspend or withhold any unpaid performance-related remuneration and long-term incentive awards; and/or

(b) recover all or part of any performance-related remuneration and long-term incentive awards previously paid in respect of the relevant period.

第七章 附 则
CHAPTER 7 MISCELLANEOUS

第十八条 本制度未尽事宜，按国家有关法律、法规、部门规章、规范性文件及公司章程的规定执行。本制度的规定如与国家日后颁布或修订的法律、法规、部门规章、规范性文件或经合法程序修订后的公司章程的规定不一致，按后者的规定执行。

Article 18 Any matters not covered by this Remuneration Policy shall be governed by the applicable laws, regulations, departmental rules and regulatory documents, as well as the Articles of Association of the Company. In the event of any inconsistency between this Remuneration Policy and any laws, regulations, departmental rules or regulatory documents subsequently promulgated or amended, or the Articles of Association of the Company as duly amended from time to time, the provisions of such laws, regulations, departmental rules, regulatory documents or Articles of Association shall prevail.

第十九条 本制度解释权归属公司董事会薪酬与考核委员会。

Article 19 This Remuneration Policy shall be interpreted by the Remuneration Committee.

第二十条 本制度自股东会决议通过之日起生效。

Article 20 This Remuneration Policy shall take effect upon its approval by the shareholders in general meeting.

NOTICE OF EXTRAORDINARY GENERAL MEETING

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED

(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)
(the "**Company**")

NOTICE OF EXTRAORDINARY GENERAL MEETING

IMPORTANT NOTE FOR S-SHARE SHAREHOLDERS

The Company issued a notice of the Extraordinary General Meeting on 15 July 2026 in accordance with the notice period prescribed under applicable PRC law.

This updated notice of Extraordinary General Meeting, issued in compliance with the listing rules of the Singapore Exchange Securities Trading Limited, supersedes the notice announced by the Company on 15 July 2026.

NOTICE IS HEREBY GIVEN that an extraordinary general meeting ("**EGM**" or "**Extraordinary General Meeting**") of the Company will be held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the People's Republic of China (the "**PRC**") 300193 (concurrently, via video conferencing at 171 Chin Swee Road, CES Centre, Level 2, #02-14, Singapore 169877 for holders of the S-Shares ("**S-Share Shareholders**") in Singapore) on Friday, 31 July 2026 at 2:00 p.m..

*Unless otherwise defined, all capitalised terms used in this Notice of EGM which are not defined herein shall have the same meanings ascribed to them in the circular issued by the Company to its Shareholders dated 16 July 2026 (the "**Circular**").*

To consider and, if thought fit, approve the following resolutions, with or without modifications:

Resolution 1: To consider and approve the proposed adoption of the remuneration policy for directors and senior management (《董事、高级管理人员薪酬管理制度》); and

Resolution 2: To consider and approve the directors' remuneration proposal for 2026 (《2026年度董事薪酬方案》).

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
16 July 2026

Notes:

1. The EGM will be held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the PRC 300193 (concurrently, via video conferencing at 171 Chin Swee Road, CES Centre, Level 2, #02-14, Singapore 169877 for S-Share Shareholders in Singapore) on Friday, 31 July 2026 at 2:00 p.m..

2. EGM documents. Printed copies of the circular dated 16 July 2026 issued by the Company (the "**Circular**"), together with this updated notice of EGM (the "**Notice of EGM**") and the accompanying Proxy Form, will be sent to S-Share Shareholders. The Circular, this Notice of EGM, and the Proxy Form have also been, or will also be, made available via SGXNet and on the Company's website at www.jydrt.com.cn. S-Share Shareholders and investors are advised to check SGXNet and/or the Company's website at www.jydrt.com.cn regularly for the latest updates.

3. Shareholders' questions and answers. S-Share Shareholders and duly appointed proxy or proxies will be able to attend the EGM in person and ask questions relating to the resolutions to be tabled for approval at the EGM.

   However, S-Share Shareholders are encouraged to raise their questions (if any) as early as possible in advance of the EGM, and in any event by **5:00 p.m.** on **Sunday**, **26 July 2026** (being not less than seven (7) calendar days after the date of the Notice of EGM) and can submit substantial and relevant questions relating to the resolutions to be tabled for approval at the EGM, in advance of the EGM, in the following manner:

   (a) by email to drt600329@163.com; or

   (b) by post to the Company's S-Shares Registrar and Singapore Transfer Office, Boardroom Corporate & Advisory Services Pte. Ltd., at 1 Harbourfront Avenue, Keppel Bay Tower #14-07, Singapore 098632.

   S-Share Shareholders who submit questions in advance of the EGM should provide their full name, address, contact number, email address and the manner in which they hold Shares (if you hold Shares directly, please provide your account number with The Central Depository (Pte) Limited; otherwise, please state if you hold your Shares through the Central Provident Fund Investment Scheme ("**CPF**") or the Supplementary Retirement Scheme ("**SRS**") or other Relevant Intermediary), for our verification purposes. "**Relevant Intermediary**" means (a) a banking corporation licensed under the Banking Act 1970 of Singapore or a wholly-owned subsidiary of such a banking corporation, whose business includes the provision of nominee services and who holds shares in that capacity, (b) a person holding a capital markets services licence to provide custodial services for securities under the Securities and Futures Act 2001 of Singapore and who holds shares in that capacity, or (c) the CPF Board established by the Central Provident Fund Act 1953 of Singapore, in respect of shares purchased under the subsidiary legislation made under that Act providing for the making of investments from the contributions and interest standing to the credit of members of the CPF, if the Board holds those shares in the capacity of an intermediary pursuant to or in accordance with that subsidiary legislation.

   The Company will endeavour to answer all substantial and relevant questions in relation to the resolutions to be tabled for approval at the EGM prior to or at the EGM. **Where substantially similar questions are received, the Company may consolidate such questions and consequently not all questions may be individually addressed.**

   The Company will also publish the minutes of the EGM, which will include substantial and relevant questions relating to the resolutions to be tabled for approval at the EGM and the responses from the Board and/or management of the Company to such questions, via SGXNet and on the Company's website at www.jydrt.com.cn within one (1) month after the date of the EGM.

4. Voting. A Shareholder (whether individual or corporate, including Relevant Intermediaries) who is entitled to attend and vote at the EGM may appoint one (1) or more persons (who need not also be Shareholder(s)) to act as his/her/its proxy(ies) to attend and vote on his/her/its behalf at the EGM. Where a Shareholder appoints more than one (1) proxy, the appointments shall be deemed to be alternative unless he/she/it specifies the proportion of his/her/its shareholding (expressed as a percentage of the whole) to be represented by each proxy.

   If the appointor is a corporation, the instrument of proxy must be executed under seal or by the hand of its duly authorised officer or attorney.

   A S-Share Shareholder (whether individual or corporate) can also choose to appoint the Chairman of the EGM as his/her/its proxy, but this is not mandatory. The Chairman of the EGM, as proxy, need not be a Shareholder of the Company. Where a S-Share Shareholder (whether individual or corporate) appoints the Chairman of the EGM as his/her/its proxy, he/she/it must give specific instructions as to voting, or abstentions from voting, in the Proxy Form. **In the absence of specific instructions, the appointment of the Chairman of the EGM as his/her/its proxy for that resolution will be treated as invalid.**

   Where a S-Share Shareholder (whether individual or corporate) appoints one (1) or more persons (other than the Chairman of the EGM) as his/her/its proxy(ies), he/she/it must give specific instructions as to voting, or abstentions from voting, in the Proxy Form. **In the absence of specific instructions, the proxy(ies) may vote or abstain from voting on the resolution(s) at his/her/their discretion.**

   The Proxy Form has been, or will be, made available via SGXNet and may also be accessed at the Company's website at www.jydrt.com.cn.

Investors who hold Shares under the CPF ("**CPF Investor**") and/or the SRS ("**SRS Investor**") (as applicable) and wish to vote should inform their respective CPF Agent Banks and/or SRS Operators to submit their votes at least **seven (7)** working days before the date of the EGM (i.e. by **5:00 p.m.** on **Tuesday, 21 July 2026**). **The Proxy Form is not valid for use by CPF Investors and SRS Investors and shall be ineffective for all intents and purposes if used or purported to be used by them.**

The duly completed Proxy Form must be submitted by S-Share Shareholders to the Company in the following manner:

(a) if submitted by post, be lodged with the Company's S-Shares Registrar and Singapore Transfer Office, Boardroom Corporate & Advisory Services Pte. Ltd., at 1 Harbourfront Avenue, Keppel Bay Tower #14-07, Singapore 098632; or

(b) if submitted electronically, via email to the Company's S-Shares Registrar and Singapore Transfer Office at Srs.Proxy@boardroomlimited.com,

in either case, by no later than **2:00 p.m.** on **Wednesday**, **29 July 2026**.

S-Share Shareholders are strongly encouraged to submit completed Proxy Forms electronically via email.

A S-Share Shareholder who wishes to submit an instrument of proxy must first complete and sign the Proxy Form, before submitting it by post to the address provided above, or before scanning and sending it by email to the email address provided above. If a S-Share Shareholder is a corporation, the Proxy Form must be executed under seal or by the hand of its duly authorised officer or attorney.

The completion and return of the instrument appointing a proxy(ies) by a Shareholder does not preclude such Shareholder from attending, speaking and voting in person at the EGM if such Shareholder subsequently decides to do so. The appointment of the proxy(ies) for the EGM will be deemed to be revoked if the Shareholder attends the EGM in person and in such event, the Company reserves the right to refuse to admit any person or persons appointed under the relevant instrument appointing a proxy(ies) to the EGM.

5. The EGM in Tianjin, PRC is expected to last for half a day and all accommodation and other expenses incurred by a Shareholder or his/her/its proxy(ies) in connection with his/her/its attendance at the EGM shall be borne by that Shareholder.

6. **Personal data privacy**: By (1) submitting a proxy form appointing a proxy(ies) and/or representative(s) to attend, speak and vote at the EGM and/or any adjournment thereof, (2) submitting any question prior to the EGM, a Shareholder of the Company (a) consents to the collection, use and disclosure of the Shareholder's personal data by the Company (or its agents or service providers) for the purposes of (i) the processing and administration by the Company (or its agents or service providers) of proxies and representatives appointed for the EGM (including any adjournment thereof), (ii) the preparation and compilation of the attendance lists, minutes and other documents relating to the EGM (including any adjournment thereof), (iii) the addressing of substantial and relevant questions relating to the resolution(s) to be tabled for approval at the EGM from Shareholders received prior to and/or at the EGM and if necessary, the follow-up with Shareholders in relation to such questions, and (iv) in order for the Company (or its agents or service providers) to comply with any applicable laws, listing rules, regulations and/or guidelines (collectively, the "**Purposes**"); (b) warrants that where a Shareholder discloses the personal data of such Shareholder's proxy(ies) and/or representative(s) to the Company (or its agents or service providers), such Shareholder has obtained the prior consent of such proxy(ies) and/or representative(s) for the collection, use and disclosure by the Company (or its agents or service providers) of the personal data of such proxy(ies) and/or representative(s) for the Purposes; and (c) agrees that the Shareholder will indemnify the Company in respect of any penalties, liabilities, claims, demands, losses and damages as a result of the Shareholder's breach of warranty.

PROXY FORM

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED

(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)
(the "**Company**")

EXTRAORDINARY GENERAL MEETING
PROXY FORM

(You are advised to read the notes below before completing this form)

IMPORTANT

1. The EGM will be held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the PRC 300193 (concurrently, via video conferencing at 171 Chin Swee Road, CES Centre, Level 2, #02-14, Singapore 169877 for S-Share Shareholders in Singapore) on Friday, 31 July 2026 at 2:00 p.m..
2. A S-Share Shareholder (whether individual or corporate) can choose to appoint the Chairman of the EGM as his/her/its proxy, but this is not mandatory. The Chairman of the EGM, as proxy, need not be a Shareholder of the Company. Where a S-Share Shareholder (whether individual or corporate) appoints the Chairman of the EGM as his/her/its proxy, he/she/it must give specific instructions as to voting, or abstentions from voting, in this Proxy Form. **In the absence of specific instructions, the appointment of the Chairman of the EGM as his/her/its proxy for that resolution will be treated as invalid.**
3. Where a S-Share Shareholder (whether individual or corporate) appoints one (1) or more persons (other than the Chairman of the EGM) as his/her/its proxy(ies), he/she/it must give specific instructions as to voting, or abstentions from voting, in this Proxy Form. **In the absence of specific instructions, the proxy(ies) may vote or abstain from voting on the resolution(s) at his/her/their discretion.**
4. Investors who hold Shares under the CPF ("**CPF Investor**") and/or the SRS ("**SRS Investor**") (as applicable) and wish to vote should inform their respective CPF Agent Banks and/or SRS Operators to submit their votes at least **seven (7)** working days before the date of the EGM (i.e. by **5:00 p.m.** on **Tuesday, 21 July 2026**). **The Proxy Form is not valid for use by CPF Investors and SRS Investors and shall be ineffective for all intents and purposes if used or purported to be used by them.**
5. **Personal Data Privacy**: By submitting this Proxy Form, the S-Share Shareholders accepts and agrees to the personal data privacy terms set out in the Company's Notice of EGM dated 16 July 2026.
6. Please read the notes overleaf which contain instructions on, *inter alia*, the appointment of a proxy(ies) by a S-Share Shareholder to attend, speak and vote on his/her/its behalf at the EGM.

I/We*, ______________________________ (Name)

with NRIC/Passport/Company Registration Number ______________________________

of ______________________________ (Address)

being a member/members of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (the "**Company**"), hereby appoint:

Name	**NRIC/Passport Number**	**Proportion of Shareholdings**	
		No. of Shares	**%**
Address			

and/or* (delete as appropriate)

Name	**NRIC/Passport Number**	**Proportion of Shareholdings**	
		No. of Shares	**%**
Address			

or failing whom, or if no persons are named above, the Chairman of the Extraordinary General Meeting as my/our* proxy/proxies* to attend, speak and vote for me/us* on my/our* behalf at the Extraordinary General Meeting of the Company ("**EGM**") to be held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the PRC 300193 (concurrently, via video conferencing at 171 Chin Swee Road, CES Centre, Level 2, #02-14, Singapore 169877 for S-Share Shareholders in Singapore) on Friday, 31 July 2026 at 2:00 p.m. and at any adjournment thereof.

I/We* direct my/our* proxy/proxies* to vote on the resolutions to be proposed at the EGM as indicated hereunder. If no specific direction as to voting is given or in the event of any other matter arising at the EGM and at any adjournment thereof, the proxy/proxies* (except where the Chairman of the EGM has been appointed as proxy) may vote or abstain from voting at his/her/their discretion. **Where the Chairman of the EGM is appointed as proxy, and no specific instructions as to voting, or abstentions from voting are given, the appointment of the Chairman of the EGM as proxy for that resolution will be treated as invalid.**

(Voting will be conducted by poll. If you wish your proxy or proxies to exercise all your votes "For", "Against" or to "Abstain" from voting, please indicate with a tick (√) or a cross (X) within the box provided. Alternatively, please indicate the number of votes as appropriate. If you mark the abstain box for a particular resolution, you are directing your proxy or proxies not to vote on that resolution on a poll and your votes will not be counted in computing the required majority on a poll.)

No.	**Resolution(s) relating to:**	**For**	**Against**	**Abstain**
1.	To consider and approve the proposed adoption of the remuneration policy for directors and senior management (《董事、高级管理人员薪酬管理制度》)			
2.	To consider and approve the directors' remuneration proposal for 2026 (《2026年度董事薪酬方案》)			

*Delete as appropriate

Dated this ________ day of ________________ 2026

Total number of Shares in:	**No. of Shares**[Note 1]
(a) Depository Register	
(b) Register of Members	

____

Signature(s) of Shareholder(s) or
Common Seal of Corporate Shareholder

IMPORTANT: PLEASE READ NOTES OVERLEAF BEFORE COMPLETING THIS PROXY FORM

PROXY FORM

Notes:

1. Please insert the total number of Shares held by you. If you have Shares entered against your name in the Depository Register (as defined in Section 81SF of the Securities and Futures Act 2001 of Singapore), you should insert that number of Shares. If you have Shares registered in your name in the Register of Members of the Company, you should insert that number of Shares. If you have Shares entered against your name in the Depository Register and Shares registered in your name in the Register of Members, you should insert the aggregate number of Shares entered against your name in the Depository Register and registered in your name in the Register of Members. **If no number is inserted, this instrument of proxy will be deemed to relate to all the Shares held by you.**

2. A Shareholder (whether individual or corporate, including Relevant Intermediaries (as defined in the Notice of EGM)) who is entitled to attend and vote at the EGM may appoint one (1) or more persons (who need not also be Shareholder(s)) to act as his/her/its proxy(ies) to attend and vote on his/her/its behalf at the EGM. Where a Shareholder appoints more than one (1) proxy, the appointment shall be deemed to be alternative unless he/she/it specifies the proportion of his/her/its shareholding (expressed as a percentage of the whole) to be represented by each proxy.

   If the appointor is a corporation, the instrument of proxy must be executed under seal or by the hand of its duly authorised officer or attorney.

   A S-Share Shareholder (whether individual or corporate) can also choose to appoint the Chairman of the EGM as his/her/its proxy, but this is not mandatory. The Chairman of the EGM, as proxy, need not be a Shareholder of the Company. Where a S-Share Shareholder (whether individual or corporate) appoints the Chairman of the EGM as his/her/its proxy, he/she/it must give specific instructions as to voting, or abstentions from voting, in this Proxy Form. **In the absence of specific instructions, the appointment of the Chairman of the EGM as his/her/its proxy for that resolution will be treated as invalid**.

   Where a S-Share Shareholder (whether individual or corporate) appoints one (1) or more persons (other than the Chairman of the EGM) as his/her/its proxy(ies), he/she/it must give specific instructions as to voting, or abstentions from voting, in this Proxy Form. **In the absence of specific instructions, the proxy(ies) may vote or abstain from voting on the resolution(s) at his/her/their discretion**;

3. CPF Investors and/or SRS Investors (as applicable) who wish to vote should inform their respective CPF Agent Banks and/or SRS Operators to submit their votes at least **seven (7)** working days before the date of the EGM (i.e. by **5:00 p.m.** on **Tuesday, 21 July 2026**). **This Proxy Form is not valid for use by CPF Investors and SRS Investors and shall be ineffective for all intents and purposes if used or purported to be used by them.**

4. The duly completed Proxy Form must be submitted by S-Share Shareholders to the Company in the following manner:

   (a) if submitted by post, be lodged with the Company's S-Shares Registrar and Singapore Transfer Office, Boardroom Corporate & Advisory Services Pte. Ltd., at 1 Harbourfront Avenue, Keppel Bay Tower #14-07, Singapore 098632; or

   (b) if submitted electronically, via email to the Company's S-Shares Registrar and Singapore Transfer Office at Srs.Proxy@boardroomlimited.com,

   in either case, by no later than **2:00 p.m.** on **Wednesday**, **29 July 2026**.

   S-Share Shareholders are strongly encouraged to submit completed Proxy Forms electronically via email.

   A S-Share Shareholder who wishes to submit an instrument of proxy must first complete and sign the Proxy Form, before submitting it by post to the address provided above, or before scanning and sending it by email to the email address provided above. If a S-Share Shareholder is a corporation, the instrument of proxy must be executed under seal or by the hand of its duly authorised officer or attorney. Where an instrument appointing a proxy(ies) and/or representative(s) is signed on behalf of the appointor by an attorney, the letter or power of attorney or a duly certified copy thereof must (failing previous registration with the Company) be lodged with the instrument of proxy, failing which the instrument may be treated as invalid.

5. The completion and return of the instrument appointing a proxy(ies) by a Shareholder does not preclude such Shareholder from attending, speaking and voting in person at the EGM if such Shareholder subsequently decides to do so. The appointment of the proxy(ies) for the EGM will be deemed to be revoked if the Shareholder attends the EGM in person and in such event, the Company reserves the right to refuse to admit any person or persons appointed under the relevant instrument appointing a proxy(ies) to the EGM.

General:

The Company shall be entitled to reject the instrument appointing a proxy or proxies if it is incomplete, improperly completed, illegible, or where the true intentions of the appointor are not ascertainable from the instructions of the appointor specified in the instrument appointing a proxy or proxies. In addition, in the case of S-Share Shareholders whose Shares are deposited with The Central Depository (Pte) Limited ("**CDP**"), the Company shall be entitled to reject any such instrument appointing a proxy or proxies lodged if such S-Share Shareholder, being the appointor, is not shown to have Shares entered against his/her/its name in the Depository Register as at forty-eight (48) hours before the time appointed for holding the EGM, as certified by the CDP to the Company.

Personal data privacy:

By submitting an instrument appointing a proxy(ies) and/or representative(s), S-Share Shareholders accept and agree to the personal data privacy terms set out in the Notice of EGM dated 16 July 2026.

This page has been intentionally left blank.